3-(dipropylcarbamoyl)-5-[methyl(methylsulfonyl)amino]benzoic acid | 1143523-15-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(dipropylcarbamoyl)-5-[methyl(methylsulfonyl)amino]benzoic acid
• CAS: 1143523-15-2
• 化学式: C₁₆H₂₄N₂O₅S
• 分子量: 356.443
• InChiKey: KCSVAMGVPRWXSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(dipropylcarbamoyl)-5-[methyl(methylsulfonyl)amino]benzoic acid 、 在 盐酸 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (1S,2R)-N-{1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl}-N',N'-dipropyl-5-[methyl(methylsulfonyl)amino]isophthalamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase

  摘要：

  To explore novel effective drugs for the treatment of Alzheimer's disease (AD), a series of dual inhibitors of acetylcholineterase (AChE) and beta-secretase (BACE-1) were designed based on the multi-target-directed ligands strategy. Among them, inhibitor 28 exhibited good dual potency in enzyme inhibitory potency assay (BACE-1: IC50 = 0.567 mu M; AChE: IC50 = 1.83 mu M), and also showed excellent inhibitory effects on Ab production of APP transfected HEK293 cells (IC50 = 98.7 nM) and mild protective effect against hydrogen peroxide (H2O2)-induced PC12 cell injury. Encouragingly, intracerebroventricular injection of 28 into amyloid precursor protein (APP) transgenic mice caused a 29% reduction of A beta(1-40) production. Therefore, 28 was demonstrated as a good lead compound for the further study and more importantly, the strategy of AChE and BACE-1 dual inhibitors might be a promising direction for developing novel drugs for AD patients. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.067
• 作为产物：
  描述：

  methyl 3-(dipropylcarbamoyl)-5-(N-methylmethylsulfonamido)benzoate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-(dipropylcarbamoyl)-5-[methyl(methylsulfonyl)amino]benzoic acid
  参考文献：
  名称：

  Aspartyl protease inhibitors

  摘要：

  本发明提供具有以下公式的化合物：1其中R1、R′、R2、R3、R3′、R4、X1、X2和X3如本文所定义，以及其药物组合物。本发明还提供抑制蛋白酶的方法，更具体地是抑制天冬氨酸蛋白酶。在某些实施方式中，这些化合物抑制BACE（β-APP剪切酶），因此在治疗或预防大脑中存在β-淀粉样沉积的疾病（包括但不限于阿尔茨海默病）方面是有用的。本发明还提供制备本发明化合物的方法。

  公开号：

  US20040147454A1

文献信息

• Aspartyl protease inhibitors
  申请人：——

  公开号：US20040147454A1

  公开（公告）日：2004-07-29

  The present invention provides compounds having the formula: 1 wherein R 1 , R′, R 2 , R 3 , R 3′ , R 4 , X 1 , X 2 and X 3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (&bgr;-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by &bgr;-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

  本发明提供具有以下公式的化合物：1其中R1、R′、R2、R3、R3′、R4、X1、X2和X3如本文所定义，以及其药物组合物。本发明还提供抑制蛋白酶的方法，更具体地是抑制天冬氨酸蛋白酶。在某些实施方式中，这些化合物抑制BACE（β-APP剪切酶），因此在治疗或预防大脑中存在β-淀粉样沉积的疾病（包括但不限于阿尔茨海默病）方面是有用的。本发明还提供制备本发明化合物的方法。
• Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase
  作者：Yiping Zhu、Kun Xiao、Lanping Ma、Bin Xiong、Yan Fu、Haiping Yu、Wei Wang、Xin Wang、Dingyu Hu、Hongli Peng、Jingya Li、Qi Gong、Qian Chai、Xican Tang、Haiyan Zhang、Jia Li、Jingkang Shen

  DOI：10.1016/j.bmc.2008.12.067

  日期：2009.2

  To explore novel effective drugs for the treatment of Alzheimer's disease (AD), a series of dual inhibitors of acetylcholineterase (AChE) and beta-secretase (BACE-1) were designed based on the multi-target-directed ligands strategy. Among them, inhibitor 28 exhibited good dual potency in enzyme inhibitory potency assay (BACE-1: IC50 = 0.567 mu M; AChE: IC50 = 1.83 mu M), and also showed excellent inhibitory effects on Ab production of APP transfected HEK293 cells (IC50 = 98.7 nM) and mild protective effect against hydrogen peroxide (H2O2)-induced PC12 cell injury. Encouragingly, intracerebroventricular injection of 28 into amyloid precursor protein (APP) transgenic mice caused a 29% reduction of A beta(1-40) production. Therefore, 28 was demonstrated as a good lead compound for the further study and more importantly, the strategy of AChE and BACE-1 dual inhibitors might be a promising direction for developing novel drugs for AD patients. (c) 2009 Elsevier Ltd. All rights reserved.